XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Fundamental Analysis

NASDAQ:XOMAO • US98419J4040

25.36 USD
+0.05 (+0.2%)
Last: Feb 13, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to XOMAO. XOMAO was compared to 523 industry peers in the Biotechnology industry. There are concerns on the financial health of XOMAO while its profitability can be described as average. XOMAO is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • XOMAO had positive earnings in the past year.
  • XOMAO had a positive operating cash flow in the past year.
  • In multiple years XOMAO reported negative net income over the last 5 years.
  • In multiple years XOMAO reported negative operating cash flow during the last 5 years.
XOMAO Yearly Net Income VS EBIT VS OCF VS FCFXOMAO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • With an excellent Return On Assets value of 3.75%, XOMAO belongs to the best of the industry, outperforming 89.87% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 9.14%, XOMAO belongs to the top of the industry, outperforming 92.54% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.31%, XOMAO belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROIC 3.31%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAO Yearly ROA, ROE, ROICXOMAO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • Looking at the Profit Margin, with a value of 20.96%, XOMAO belongs to the top of the industry, outperforming 93.69% of the companies in the same industry.
  • XOMAO's Operating Margin of 20.92% is amongst the best of the industry. XOMAO outperforms 95.22% of its industry peers.
Industry RankSector Rank
OM 20.92%
PM (TTM) 20.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAO Yearly Profit, Operating, Gross MarginsXOMAO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMAO is destroying value.
  • XOMAO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, XOMAO has more shares outstanding
  • Compared to 1 year ago, XOMAO has a worse debt to assets ratio.
XOMAO Yearly Shares OutstandingXOMAO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAO Yearly Total Debt VS Total AssetsXOMAO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.57, we must say that XOMAO is in the distress zone and has some risk of bankruptcy.
  • XOMAO has a Altman-Z score (-4.57) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.87 indicates that XOMAO is somewhat dependend on debt financing.
  • XOMAO has a Debt to Equity ratio of 0.87. This is in the lower half of the industry: XOMAO underperforms 72.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACC0.27
WACC12.46%
XOMAO Yearly LT Debt VS Equity VS FCFXOMAO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 3.91 indicates that XOMAO has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.91, XOMAO perfoms like the industry average, outperforming 46.65% of the companies in the same industry.
  • A Quick Ratio of 3.91 indicates that XOMAO has no problem at all paying its short term obligations.
  • XOMAO has a Quick ratio (3.91) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 3.91
XOMAO Yearly Current Assets VS Current LiabilitesXOMAO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • XOMAO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 135.71%, which is quite impressive.
  • The Revenue has grown by 103.96% in the past year. This is a very strong growth!
  • The Revenue has been growing by 9.17% on average over the past years. This is quite good.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%

3.2 Future

  • The Earnings Per Share is expected to grow by 37.32% on average over the next years. This is a very strong growth
  • XOMAO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.64% yearly.
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMAO Yearly Revenue VS EstimatesXOMAO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
XOMAO Yearly EPS VS EstimatesXOMAO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 33.81, XOMAO can be considered very expensive at the moment.
  • 92.35% of the companies in the same industry are more expensive than XOMAO, based on the Price/Earnings ratio.
  • XOMAO's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.97.
  • A Price/Forward Earnings ratio of 80.66 indicates a quite expensive valuation of XOMAO.
  • XOMAO's Price/Forward Earnings ratio is rather cheap when compared to the industry. XOMAO is cheaper than 88.15% of the companies in the same industry.
  • XOMAO is valuated expensively when we compare the Price/Forward Earnings ratio to 27.96, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.81
Fwd PE 80.66
XOMAO Price Earnings VS Forward Price EarningsXOMAO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XOMAO indicates a rather cheap valuation: XOMAO is cheaper than 92.54% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.83
XOMAO Per share dataXOMAO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • XOMAO's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y46.72%
EPS Next 3Y37.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • XOMAO has a Yearly Dividend Yield of 8.26%, which is a nice return.
  • Compared to an average industry Dividend Yield of 1.14, XOMAO pays a better dividend. On top of this XOMAO pays more dividend than 99.62% of the companies listed in the same industry.
  • XOMAO's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
Industry RankSector Rank
Dividend Yield 8.26%

5.2 History

  • XOMAO has been paying a dividend for over 5 years, so it has already some track record.
  • XOMAO has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAO Yearly Dividends per shareXOMAO Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • XOMAO pays out 55.43% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP55.43%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
XOMAO Yearly Income VS Free CF VS DividendXOMAO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M
XOMAO Dividend Payout.XOMAO Dividend Payout, showing the Payout Ratio.XOMAO Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (2/13/2026, 8:00:02 PM)

25.36

+0.05 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-05
Inst Owners67.66%
Inst Owner ChangeN/A
Ins Owners1.79%
Ins Owner ChangeN/A
Market Cap313.96M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts84
Price Target63.16 (149.05%)
Short Float %0.05%
Short Ratio0.77
Dividend
Industry RankSector Rank
Dividend Yield 8.26%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years3
Ex-Date01-02
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)-4.75%
PT rev (3m)16.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100.88%
EPS NY rev (1m)7.34%
EPS NY rev (3m)115.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.15%
Valuation
Industry RankSector Rank
PE 33.81
Fwd PE 80.66
P/S 6.66
P/FCF N/A
P/OCF 57.41
P/B 2.91
P/tB 4.95
EV/EBITDA 30.83
EPS(TTM)0.75
EY2.96%
EPS(NY)0.31
Fwd EY1.24%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.74%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.21
PEG (5Y)N/A
Graham Number12.13
Profitability
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROCE 4.2%
ROIC 3.31%
ROICexc 4.14%
ROICexgc 5.42%
OM 20.92%
PM (TTM) 20.96%
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA 7.77
Cap/Depr 880.03%
Cap/Sales 42.84%
Interest Coverage 0.83
Cash Conversion 45.03%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 3.91
Altman-Z -4.57
F-Score6
WACC12.46%
ROIC/WACC0.27
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.59%
EBIT Next 3Y49.29%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A

XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO FAQ

What is the ChartMill fundamental rating of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

ChartMill assigns a fundamental rating of 5 / 10 to XOMAO.


What is the valuation status for XOMAO stock?

ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO). This can be considered as Fairly Valued.


Can you provide the profitability details for XOMA ROYALTY CORP - XOMA 8 3/8 PERP?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a profitability rating of 5 / 10.


What are the PE and PB ratios of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

The Price/Earnings (PE) ratio for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is 33.81 and the Price/Book (PB) ratio is 2.91.


What is the earnings growth outlook for XOMA ROYALTY CORP - XOMA 8 3/8 PERP?

The Earnings per Share (EPS) of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is expected to grow by 157.93% in the next year.